Advertisement
News
Subscribe to MDT Magazine News

Regeneron Announces March 2011 Investor Conference Presentations

February 23, 2011 6:34 am | by Bio-Medicine.Org | Comments

TARRYTOWN, N.Y., Feb. 23, 2011 /- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) will webcast management presentations at the following investor conferences: Citi 2011 Global Healthcare Conference at 9:00 a.m. Eastern Time on Tuesday, March 1, 2011 RBC Capital Markets' 2011 Healthcare...

TOPICS:

Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City

February 23, 2011 6:34 am | by Bio-Medicine.Org | Comments

BASKING RIDGE, N.J., Feb. 23, 2011 /- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be speaking and participating on a...

TOPICS:

Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts

February 23, 2011 6:33 am | by Bio-Medicine.Org | Comments

WOONSOCKET, R.I., Feb. 23, 2011 /- Xenogenics Corporation ("Xenogenics"), a majority owned subsidiary of MultiCell Technologies, Inc. (OTC Bulletin Board MCET), is pleased to announce it has retained the Emmes Group to assist with the development and execution of its capital formation...

TOPICS:
Advertisement

Solos Endoscopy, Inc. To Introduce New Urology Instrument Line

February 23, 2011 6:32 am | by Bio-Medicine.Org | Comments

BOSTON, Feb. 23, 2011 /- Solos Endoscopy, Inc. (Pink Sheets: SNDY ) is pleased to announce that the Company is set to introduce a new product line consisting of urology surgical and diagnostic instruments. The line will feature approximately 10 instruments, six of which are modifications...

TOPICS:

Manufacturers Large and Small Answer Nationwide Call to Define Future of U.S. Manufacturing at imX

February 23, 2011 5:39 am | by Society of Manufacturing Engineers | Comments

LAS VEGAS, Feb. 23, 2011 — From some of the United States' largest industrial technology innovators to the heads of small machine shops and providers of workholding, drilling and grinding tools, manufacturers from across the country will gather this fall at an unprecedented industry...

Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing

February 23, 2011 5:38 am | by Bio-Medicine.Org | Comments

HOPKINTON, Mass., Feb. 23, 2011 /- Caliper Life Sciences, Inc. (Nasdaq: CALP ) and Covaris Inc., Woburn, Mass., today announced a co-marketing agreement which will leverage Covaris' acoustic DNA shearing platforms and Caliper's automation and microfluidics technologies to develop...

TOPICS:

Generex Announces New Treatment IND Site for the USFDA Expanded Access Treatment IND Program for Generex Oral-lynâ„¢ in the United States

February 23, 2011 5:38 am | by Bio-Medicine.Org | Comments

WORCESTER, Mass., Feb. 23, 2011 /- Generex Biotechnology Corporation ( www.generex.com ) (OTC Bulletin Board: GNBT ) announced today that Stamford Hospital has agreed to participate in the United States Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug...

TOPICS:

Healthpoint Launches New Corporate Identity

February 23, 2011 5:38 am | by Bio-Medicine.Org | Comments

FORT WORTH, Texas, Feb. 23, 2011 /- Healthpoint today announced the launch of a new corporate identity featuring a new company name, Healthpoint Biotherapeutics, along with an updated brandmark and corporate tagline, "The Science of Healing™". Together, the new corporate identity is...

TOPICS:
Advertisement

Sunridge Signs Distribution Agreement for Turkey

February 23, 2011 5:38 am | by Bio-Medicine.Org | Comments

FOUNTAIN HILLS, Ariz., Feb. 23, 2011 /- Sunridge International (OTC Bulletin Board/OTCQB: SNDZ), announced today the signing of an exclusive distribution contract for Turkey.  Based on Turkey's population of approximately 75 million people, the 5-year contract with New Amsterdam...

TOPICS:

St. Joseph Health System Selects Allscripts Care Management and Homecare Solutions

February 23, 2011 5:38 am | by Bio-Medicine.Org | Comments

CHICAGO and ORANGE, Calif., Feb. 23, 2011 /- St. Joseph Health System (SJHS), a $4.6 billion not-for-profit Catholic healthcare system based in Orange, CA that provides a broad range of medical services in California, West Texas and Eastern New Mexico, has selected Care Management™...

TOPICS:

Speck Design Delivers Solutions for Two Complex Consumer Products for Social Good

February 23, 2011 5:37 am | by Bio-Medicine.Org | Comments

PALO ALTO, Calif., Feb. 23, 2011 /- Complications during development led two product development companies to turn to Speck Design in recent months for an inventive approach and mechanical design that would deliver top-quality products on deadline.  The first product, Zamzee, had an...

TOPICS:

Avanir Pharmaceuticals to Present at Three Conferences in March

February 23, 2011 5:36 am | by Bio-Medicine.Org | Comments

ALISO VIEJO, Calif., Feb. 23, 2011 /- Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR ) today announced that company management will present an overview of the company at the following conferences in March. Citi 2011 Global Healthcare Conference Location: Hilton New York, New York, NY...

TOPICS:

Abaxis, Inc. to Present at RBC Capital Markets' Healthcare Conference

February 23, 2011 5:35 am | by Bio-Medicine.Org | Comments

UNION CITY, Calif., Feb. 23, 2011 /- Abaxis, Inc. (Nasdaq: ABAX ), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer, will present at the RBC Capital Markets' Healthcare Conference on...

TOPICS:

European Multidisciplinary Conference in Thoracic Oncology -- press program

February 23, 2011 5:35 am | by EurekAlert | Comments

(European Society for Medical Oncology) The following studies will be presented in the Press Program of the second European Multidisciplinary Conference in Thoracic Oncology, a multipartner initiative for physicians of all medical disciplines dealing with lung cancer and other thoracic malignancies.

TOPICS:

Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation

February 23, 2011 5:35 am | by Bio-Medicine.Org | Comments

BETHESDA, Md., Feb. 23, 2011 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis, showed promising results in a Phase 3 clinical...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading